Lympro CLIA package, 2 Orphan Drug Applications for MANF,
Lympro CLIA package, 2 Orphan Drug Applications for MANF, additional MANF data, IND for Eltoprazine. If that all happens, it will be a very solid quarter.
Lots in between the lines that could come to fruition as well. Build out of ICON relationship for Lympro (Ex-US deal?). Interest from BP regarding Eltoprazine. This may not happen until 2015, but with their work on ADHD after submission for LID, Eltoprazine becomes extremely attractive. MANF biz dev activities have been mentioned, and with 2 potential orphan indications, interest will be accelerated with BP. Other orphan ocular indications will certainly garner the attention of BP players in that market. Expecting to hear something about at least one grant soon. They have been hard at work on that for some time now.
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Rosanne Cash Exhibition at the Country Music Hall of Fame The Country Music Hall of Fame and Museum is set to showcase a remarkable exhibition centered on the influential career of Rosanne Cash. This exhibition, titled "Rosanne Cash: Time Is a Mirror," will delve into her extensive journey as an artist, encompassing her evolution as a songwriter and storyteller....
Continue Reading
Transforming Moving Services for Boston Residents Boston's vibrant atmosphere has led to an increased demand for efficient and modern moving solutions. Safe Responsible Movers is dedicated to meeting these needs, offering top-notch services tailored to the specific challenges that both residents and businesses experience. With a solid reputation established over the...
Continue Reading
Endeavour Mining's Recent Share Buyback Announcement Endeavour Mining plc has made a notable step in its commitment to returning value to shareholders through the recent purchase of its ordinary shares. The company has acquired shares from Stifel Nicolaus Europe Limited, marking a significant move in its ongoing buyback program. Aggregated Information on the Share...
Continue Reading
Kristi Vassak Takes on Key Role at Lenox Advisors Lenox Advisors, an esteemed wealth management and insurance advisory firm, has appointed Kristi Vassak as Chief Operating Officer. This significant promotion reflects not only her extensive tenure but also her transformative leadership within the company. As a long-term employee who joined the firm in 2005, Vassak has...
Continue Reading
Werewolf Therapeutics Engages at Kidney Cancer Research Summit WATERTOWN, Mass. — Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), a forward-thinking biopharmaceutical company, is making strides in its mission to revolutionize cancer treatment through conditionally activated therapeutics. This approach aims to empower the body’s immune system...
Continue Reading
